Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.
Lindskog M, Laurell A, Kjellman A, Melichar B, Rey PM, Zieliński H, Villacampa F, Bigot P, Zoltan B, Parikh O, Alba DV, Jellvert Å, Flaskó T, Gallardo E, Caparrós MJR, Purkalne G, Suenaert P, Karlsson-Parra A, Ljungberg B. Lindskog M, et al. Among authors: purkalne g. Eur Urol Open Sci. 2022 Apr 26;40:38-45. doi: 10.1016/j.euros.2022.03.012. eCollection 2022 Jun. Eur Urol Open Sci. 2022. PMID: 35638086 Free PMC article.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. Vogelzang NJ, et al. JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298. JAMA Oncol. 2022. PMID: 35142815 Free PMC article. Clinical Trial.
Chromothripsis and progression-free survival in metastatic colorectal cancer.
Skuja E, Kalniete D, Nakazawa-Miklasevica M, Daneberga Z, Abolins A, Purkalne G, Miklasevics E. Skuja E, et al. Among authors: purkalne g. Mol Clin Oncol. 2017 Feb;6(2):182-186. doi: 10.3892/mco.2017.1123. Epub 2017 Jan 2. Mol Clin Oncol. 2017. PMID: 28357089 Free PMC article.
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
Brodowicz T, Ciuleanu TE, Radosavljevic D, Shacham-Shmueli E, Vrbanec D, Plate S, Mrsic-Krmpotic Z, Dank M, Purkalne G, Messinger D, Zielinski CC. Brodowicz T, et al. Among authors: purkalne g. Ann Oncol. 2013 Jul;24(7):1769-1777. doi: 10.1093/annonc/mdt116. Epub 2013 Apr 4. Ann Oncol. 2013. PMID: 23559149 Free article. Clinical Trial.
Deletions in metastatic colorectal cancer with chromothripsis.
Skuja E, Butane D, Nakazawa-Miklasevica M, Daneberga Z, Purkalne G, Miklasevics E. Skuja E, et al. Among authors: purkalne g. Exp Oncol. 2019 Dec;41(4):323-327. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-4.13841. Exp Oncol. 2019. PMID: 31868331
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
Markóczy Z, Sárosi V, Kudaba I, Gálffy G, Turay ÜY, Demirkazik A, Purkalne G, Somfay A, Pápai-Székely Z, Rásó E, Ostoros G. Markóczy Z, et al. Among authors: purkalne g. BMC Cancer. 2018 May 25;18(1):598. doi: 10.1186/s12885-018-4283-z. BMC Cancer. 2018. PMID: 29801465 Free PMC article. Clinical Trial.
36 results